Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Changes in iris microvasculature after horizontal strabismus surgery: anterior segment OCTA combined with synoptophore-based functional assessment.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie·2026
Same author

Asymmetric Total Synthesis of (+)-Ineleganolide.

Angewandte Chemie (International ed. in English)·2026
Same author

Vaccination Coverage, Timeliness and Adverse Events Following Immunization in Children with Medical Conditions - Shandong Province, China, 2023.

China CDC weekly·2026
Same author

<i>In situ</i> construction of pine-needle-like AgNP/Cu(OH)<sub>2</sub>/copper foam for ultrasensitive mixed-dyes analysis.

Analytical methods : advancing methods and applications·2026
Same author

Age-associated niche remodeling drives dental pulp progenitor dysfunction and fibrosis.

Communications biology·2026
Same author

Epigenetic priming with azacitidine-BEAM versus decitabine-BEAM conditioning for autologous transplantation in non-Hodgkin's lymphoma.

Bone marrow transplantation·2026

Related Experiment Video

Updated: Jun 18, 2026

Large Scale Non-targeted Metabolomic Profiling of Serum by Ultra Performance Liquid Chromatography-Mass Spectrometry UPLC-MS
07:34

Large Scale Non-targeted Metabolomic Profiling of Serum by Ultra Performance Liquid Chromatography-Mass Spectrometry UPLC-MS

Published on: March 14, 2013

12.7K

Metabolomics for hematologic malignancies: Advances and perspective.

Xinglan Li1, Mengyu Xu1, Yanying Chen2

  • 1Linyi People's Hospital, Shandong Second Medical University, Linyi, PR China.

Medicine
|September 23, 2024
PubMed
Summary

Metabolomics reveals key metabolic alterations in blood cancers like lymphoma, myeloma, and leukemia. This research offers new diagnostic and therapeutic targets for hematologic malignancies.

More Related Videos

Author Spotlight: Advancing Metabolomics Analysis of Rare Hematopoietic Stem Cells
08:28

Author Spotlight: Advancing Metabolomics Analysis of Rare Hematopoietic Stem Cells

Published on: February 23, 2024

1.8K
Identification and Quantification of Deranged Metabolites in Critically Ill Patients Using NMR-Based Metabolomics
11:02

Identification and Quantification of Deranged Metabolites in Critically Ill Patients Using NMR-Based Metabolomics

Published on: November 29, 2024

486

Related Experiment Videos

Last Updated: Jun 18, 2026

Large Scale Non-targeted Metabolomic Profiling of Serum by Ultra Performance Liquid Chromatography-Mass Spectrometry UPLC-MS
07:34

Large Scale Non-targeted Metabolomic Profiling of Serum by Ultra Performance Liquid Chromatography-Mass Spectrometry UPLC-MS

Published on: March 14, 2013

12.7K
Author Spotlight: Advancing Metabolomics Analysis of Rare Hematopoietic Stem Cells
08:28

Author Spotlight: Advancing Metabolomics Analysis of Rare Hematopoietic Stem Cells

Published on: February 23, 2024

1.8K
Identification and Quantification of Deranged Metabolites in Critically Ill Patients Using NMR-Based Metabolomics
11:02

Identification and Quantification of Deranged Metabolites in Critically Ill Patients Using NMR-Based Metabolomics

Published on: November 29, 2024

486

Area of Science:

  • Biochemistry
  • Oncology
  • Systems Biology

Background:

  • Metabolomics enables comprehensive analysis of small molecules in biological samples.
  • Metabolomic alterations are increasingly linked to the pathogenesis of hematologic malignancies.
  • Understanding these changes is crucial for advancing cancer diagnostics and therapeutics.

Purpose of the Study:

  • To review the current understanding of metabolomics in hematologic malignancies.
  • To explore the roles of glucose, amino acid, and lipid metabolism in lymphoma, myeloma, and leukemia.
  • To highlight the potential of metabolomics for early diagnosis, treatment efficacy, staging, and targeted therapy.

Main Methods:

  • Review of existing literature on metabolomics in hematologic cancers.
  • Analysis of specific metabolic pathways (glucose, amino acid, lipid) in relation to disease.
  • Examination of mechanisms and pathways involved in cancer development.

Main Results:

  • Metabolomic pathway alterations are integral to the pathogenesis of hematologic malignancies.
  • Specific metabolic dysregulations identified in lymphoma, myeloma, and leukemia.
  • Metabolomics provides insights into disease progression and potential therapeutic vulnerabilities.

Conclusions:

  • Metabolomics offers novel insights into the biology of hematologic malignancies.
  • Metabolic pathways represent promising targets for developing new diagnostic and therapeutic strategies.
  • Further research in metabolomics can lead to improved patient outcomes in blood cancers.